|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61P 35/04 | |
| A61K 38/17 |
| (11) | Patento numeris | 2111229 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 08725118.7 |
| Europos patento paraiškos padavimo data | 2008-02-01 | |
| (97) | Europos patento paraiškos paskelbimo data | 2009-10-28 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2013-04-10 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2008/001429 |
| Data | 2008-02-01 |
| (87) | Numeris | WO 2008/094708 |
| Data | 2008-08-07 |
| (30) | Numeris | Data | Šalis |
| 899070 P | 2007-02-01 | US | |
| 540 P | 2007-10-25 | US |
| (72) |
KNOPF, John, US
SEEHRA, Jasbir, US
KUMAR, Ravindra, US
|
| (73) |
Acceleron Pharma, Inc.,
128 Sidney Street, Cambridge, MA 02139,
US
|
| (54) | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
| Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |